Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cytosorbents Corporation is a medical devices business based in the US. Cytosorbents Corporation shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Cytosorbents Corporation employs 153 staff and has a trailing 12-month revenue of around USD$36.5 million.
|Latest market close||USD$8.89|
|52-week range||USD$3.6 - USD$11.74|
|50-day moving average||USD$8.4734|
|200-day moving average||USD$8.792|
|Wall St. target price||USD$14.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.529|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||6.72%|
|1 month (2020-12-16)||3.98%|
|3 months (2020-10-16)||3.92%|
|6 months (2020-07-16)||-16.84%|
|1 year (2020-01-16)||91.18%|
|2 years (2019-01-16)||19.01%|
|3 years (2018-01-16)||13.97%|
|5 years (2016-01-15)||106.26%|
|Revenue TTM||USD$36.5 million|
|Gross profit TTM||USD$17.6 million|
|Return on assets TTM||-12.38%|
|Return on equity TTM||-25.55%|
|Market capitalisation||USD$358.8 million|
TTM: trailing 12 months
There are currently 3.1 million Cytosorbents Corporation shares held short by investors – that's known as Cytosorbents Corporation's "short interest". This figure is 3.7% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Cytosorbents Corporation shares can be evaluated.
Cytosorbents Corporation's "short interest ratio" (SIR) is the quantity of Cytosorbents Corporation shares currently shorted divided by the average quantity of Cytosorbents Corporation shares traded daily (recently around 245990.64234734). Cytosorbents Corporation's SIR currently stands at 12.61. In other words for every 100,000 Cytosorbents Corporation shares traded daily on the market, roughly 12610 shares are currently held short.
However Cytosorbents Corporation's short interest can also be evaluated against the total number of Cytosorbents Corporation shares, or, against the total number of tradable Cytosorbents Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytosorbents Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cytosorbents Corporation shares in existence, roughly 70 shares are currently held short) or 0.073% of the tradable shares (for every 100,000 tradable Cytosorbents Corporation shares, roughly 73 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cytosorbents Corporation.
Find out more about how you can short Cytosorbents Corporation stock.
We're not expecting Cytosorbents Corporation to pay a dividend over the next 12 months.
Cytosorbents Corporation's shares were split on a 1:25 basis on 5 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Corporation shares which in turn could have impacted Cytosorbents Corporation's share price.
Over the last 12 months, Cytosorbents Corporation's shares have ranged in value from as little as $3.6 up to $11.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Corporation's is 0.4315. This would suggest that Cytosorbents Corporation's shares are less volatile than average (for this exchange).
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVI, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVSI, with 24-hour and historical pricing before you buy.
Steps to owning and managing EBTC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.